Overview of a Phase I clinical trial using BGB-3111 for the treatment of relapsed CLL

Tam Constantine, MD from Peter MacCallum Cancer Centre & St. Vincent’s Hospital Melbourne, Melbourne, Australia, gives an overview of the new data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on BGB-3111, a second generation Bruton’s tyrosine kinase (BTK) inhibitor. The data presented were obtained from a Phase I clinical trial, where the drug was well tolerated and demonstrated a good safety profile.